malignant tumors which have lesions located outside the liver
Conditions
Interventions
To perform radiofrequency ablation for malignant tumors located outside the liver
Sponsors
Division of Diagnostic Imaging and Minimally Invasive Therapy, Juntendo University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Tumors which are eligible for radiofrequency ablation in a solid organ or others 2)Ineligible for surgical resection or patient refusal for surgery 3)A single tumor 6 cm in diameter or three or fewer tumors all 3 cm or less in diameter 4)There are no tumors ineligible for radiofrequency ablation or, if any, tumors are much less in volume compared with those treated by radiofrequency ablation and would not determine the prognosis 5)In cases in which tumors are very likely to recur, or in which some malignant tissue is likely to remain unablated, it is necessary that patients should achieve stable disease or better response to chemotherapy or that at least some standardized regimens of chemotherapy is feasible 6)Patients who give written informed consent prior to the study
Exclusion criteria
Exclusion criteria: 1)Tumors not visualized by ultrasonography/not accessible percutaneously 2)Patients in whom ablation of the tumors is highly likely to cause damage of other organs or tissues 3)Patients with marked bleeding tendency 4)Patients with The American Society of Anesthesiologists physical state (ASA PS) 3 or more 5)Patients who cannot follow instructions because of dementia 6)Patients in whom therapeutic efficacy cannot be evaluated with contrast-enhanced CT scan or others, because of renal dysfunction or adverse reactions to contrast agents 7)Patients in whom effective measures, such as transfusion and others, cannot be used for adverse events because of religious reasons or others 8)Patients considered to be ineligible for participation in the study by the investigator or subinvestigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival Frequency of adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Local tumor progression rate Recurrence rate | — |
Countries
Japan
Contacts
Public ContactShuichiro Shiina
Juntendo University Graduate School of Medicine Division of Diagnostic Imaging and Minimally Invasive Therapy
Outcome results
None listed